Pancreatic Cancer Research

ResearcherIstanbul UniversityActive in the last 2 years

Faruk Taş

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6514-7116; OpenAlex author ID A5005531017, A5042361088. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2013: 4 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Sex Difference Has No Effect on Survival in Pancreatic Cancer. Co-author DOI 10.1007/s13193-025-02321-9↗
  2. Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer. Last author DOI 10.3390/biom8040169↗
  3. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma. Last author DOI 10.1016/j.jiac.2016.12.003↗
  4. Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma. Last author DOI 10.1016/j.bbacli.2016.10.002↗
  5. Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy. Last author PMID 27685911↗
  6. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Co-author DOI 10.1007/s00280-014-2450-8↗
  7. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Co-author DOI 10.1007/s10147-012-0474-9↗
  8. Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s12029-013-9512-8↗
  9. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s13277-013-0931-8↗
  10. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival. Co-author DOI 10.3892/mco.2013.131↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kayhan Ertürk · 2 shared papers, 2016–2026 · strength 0.69
  2. Senem Karabulut · 7 shared papers, 2013–2018 · strength 0.41
  3. Çiğdem Usul Afşar · 4 shared papers, 2016–2018 · strength 0.29
  4. Derya Duranyıldız · 3 shared papers, 2013–2014 · strength 0.13
  5. İbrahim Yıldız · 3 shared papers, 2013 · strength 0.13
  6. Didem Taştekin · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.